Introduction
============

Colorectal cancer is the third most frequent cause of cancer-related deaths in the United States [@B1]. Surgical resection is the primary treatment for patients with colorectal cancer, but \~30-50% of these patients will relapse and ultimately die after surgery [@B2]. Given the limited therapeutic options and molecular targets currently approved for the treatment of colorectal cancer, there is an urgent need for the identification of novel therapeutic targets to improve clinical outcomes.

Small non-coding RNAs (sncRNAs) have recently gained attention owing to their involvement in multiple biological processes by directly or indirectly interfering with gene expression, and dysregulation of sncRNAs has been implicated in a variety of disorders, including cancer [@B3]. sncRNAs represent a large group of RNAs that are generally less than 200 nucleotides in length, including microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), small Cajal body-specific RNAs (scaRNAs), and others. miRNAs bind to mRNA targets and negatively regulate gene expression through the degradation of target transcripts and inhibition of translation [@B4]. snoRNAs comprise a class of nucleolus-enriched sncRNAs that largely regulate the post-transcriptional maturation of ribosomal RNAs. snoRNAs are classified into C/D box snoRNAs and H/ACA box snoRNAs based on their structure and function, responsible for 2\'-O-methylation and guiding the pseudo-uridylation of nucleotides, respectively [@B5], [@B6]. In addition, certain snoRNAs can also be processed into miRNAs to influence mRNA expression [@B7]. Similarly, scaRNAs guide the methylation and pseudo-uridylation of small nuclear RNAs [@B8], [@B9]. The expression profiles of these sncRNAs tend to vary among different types of cancers, and are potential or prognostic biomarkers with possible clinical applications. To determine their prognostic or therapeutic value in colorectal cancer, in this study, we comprehensively analyzed 31 common single nucleotide polymorphisms (SNPs) of sncRNAs and their impact on the survival of patients with colorectal cancer.

Patients and Methods
====================

Patient recruitment and data collection
---------------------------------------

The present study cohort included 188 patients with colorectal cancer who underwent surgical resection at China Medical University Hospital, Taiwan between 2001 and 2007. Disease characteristics and follow-up data of these patients were obtained from their medical records. Overall survival was defined as the duration from diagnosis to death from any cause or until the last follow-up. All participants provided written informed consent before surgery. This study was approved by the Institutional Review Board of China Medical University Hospital, and was performed according to the approved guidelines.

SNP selection and genotyping
----------------------------

We identified SNPs of sncRNAs by intersection sno/miRNA table [@B10] with HapMap SNPs CHB (Han Chinese in Beijing, China) table from the UCSC table browser (NCBI36/hg18) [@B11]. SNPs with a minor allele frequency less than 0.05 and those in linkage disequilibrium in the HapMap CHB population were excluded. Thirty-eight sncRNA SNPs were initially selected for analysis. Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) and stored at -80°C until analysis. Genotyping was performed at the National Center for Genome Medicine, Taiwan, using the Agena Bioscience iPLEX matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry technology, as described previously [@B12]. Any SNP that failed the genotyping assay design, did not conform to Hardy-Weinberg equilibrium (*P* \< 0.05), was below a genotyping call rate of 0.8, or had a minor allele frequency less than 0.03 was removed (*N* = 7). Thus, a total of 31 SNPs of sncRNAs, including 10 in C/D box snoRNAs, 9 in H/ACA box snoRNAs, 7 in miRNAs, and 5 in scaRNAs, were included for further statistical analyses.

Statistical analysis
--------------------

Patient clinicopathological characteristics are summarized as the number and percentage of patients or the median and interquartile range of values. The hazard ratio (HR) and 95% confidence interval were estimated by Cox regression analysis to assess the association of clinicopathological characteristics with overall survival. The difference in overall survival according to the SNP genotypes was compared using Kaplan-Meier analysis and log-rank tests. We also performed multivariate Cox regression to determine the interdependency of genetic interactions and known prognostic factors such as age, gender, carcinoembryonic antigen (CEA) levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement [@B13]-[@B16]. The Statistical Package for the Social Sciences software version 22.0.0 (IBM, Armonk, NY, USA) was used for statistical analyses. A two-sided *P* value of \<0.05 was considered nominally significant. As we were testing 31 SNPs, the *q* value was applied to control the false discovery rate [@B17] and the association was deemed significant at the *q* \< 0.20 level.

Bioinformatics analysis
-----------------------

The publicly available SurvExpress database [@B18] was utilized to analyze the expression levels of the *hsa-miR-196a* target genes *HOXA7*, *HOXB8*, and *AKT1* on the survival of colorectal cancer patients. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway enrichment analyses were performed by DIANA-miRPath v3.0 [@B19]. This software calculates enrichment based on experimentally supported miRNA-gene interactions derived from DIANA-TarBase v7.0 [@B20].

Results
=======

The clinical and pathologic characteristics of patients with colorectal cancer and the association with overall survival are shown in Table [S1](#SM0){ref-type="supplementary-material"}. At the median follow-up duration of 60.1 months, 61 patients had died and the estimated 5-year overall survival rate was 69.3%. Univariate analysis showed that CEA levels, tumor stage, lymphovascular invasion, perineural invasion, and lymph node involvement were respectively significantly associated with overall survival (*P* ≤ 0.006).

Of the 31 sncRNA SNPs analyzed in the study, three (*ACA23* rs2290423, *hsa-mir-196a-2* rs11614913, and *U85* rs714775) showed significant effects on survival (nominal *P* ≤ 0.016, *q* \< 0.20 in all cases; Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). In the multivariate analysis adjusted for age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement, *hsa-mir-196a-2* rs11614913 and *U85* rs714775 remained significantly associated with survival (*P* ≤ 0.012, Table [2](#T2){ref-type="table"}). The HRs for death were 1.84 and 0.50 for genotypes at the rs11614913 and rs714775 locus, respectively.

SNPs of miRNAs might affect miRNA binding, the expression of its target genes, and subsequent disease progression. Previous studies have shown that *hsa-miR-196a*, the mature miRNA of *hsa-mir-196a-2*, restricts the expression of *HOXA7* and *HOXB8*, leading to activation of the *AKT1* survival pathway in colorectal cancer. Therefore, we further evaluated the prognostic role of the expression levels of the *hsa-miR-196a* target genes *HOXA7*, *HOXB8*, and *AKT1* on the survival of colorectal cancer patients using the publicly available SurvExpress Colon-Metabase dataset. The risk score for each patient was derived from each gene expression level and their Cox regression coefficients, and was used to divide patients into low- or high-risk groups using an optimization algorithm for the minimum *P* value. Low expression levels of *HOXA7* and *HOXB8* and high *AKT1* expression levels were significantly associated with poor survival in colorectal cancer patients (*P* ≤ 0.004, Figure [2](#F2){ref-type="fig"}).

In addition to the known *hsa-miR-196a* target genes, DIANA-miRPath analysis further revealed the pathways with significant enrichment of target mRNAs of *hsa-miR-196a-5p* and *hsa-miR-196a-3p*, two mature miRNAs of *hsa-mir-196a-2*. We annotated the 20 top-ranked KEGG and GO pathways through Fisher\'s exact test and false-discovery rate correction (Figure [3](#F3){ref-type="fig"}). Adherens junction, extracellular matrix receptor, proteoglycans in cancer, Hippo signaling, transcriptional misregulation in cancer, colorectal cancer, pathways in cancer, and p53 signaling pathways were the top enriched KEGG pathways.

The top biological processes in GO enrichment analysis were associated with cellular protein modification, mitotic cell cycle, and gene expression, and the top molecular functions were protein binding transcription factor activity and enzyme binding in cellular components of the nucleoplasm and cytosol. Importantly, these KEGG/GO pathways are known to be critical for controlling the development of cancers.

Discussion
==========

We conducted a comprehensive study to identify genetic variants of sncRNAs associated with the prognosis of patients with surgically resected colorectal cancer. The SNPs *hsa-mir-196a-2* rs11614913 and *U85* rs714775 were significantly associated with survival, even after adjusting for other clinical predictors and multiple testing. Further functional annotation of the predicted downstream targets demonstrated that these SNPs are associated with significant dysregulation in protein modification, cell cycle, and cell-cell interactions, which are closely related to the biological characteristics of cancer cells. Our work therefore contributes to gaining a better understanding of the role of sncRNAs in cancer, and highlights their potential as valuable molecular biomarkers in colorectal cancer.

The SNP rs11614913 is located in the 3′ passenger (3p) strand of the mature sequence of *hsa-mir-196a-2*. Patients with lung cancer carrying a variant homozygous CC genotype of rs11614913 were reported to have relatively poor survival, and the mechanism was determined to be elevated expression of mature *hsa-miR-196a* with weakened target binding of *hsa-miR-196a-3p* [@B21]. These data are consistent with our findings of a trend toward poorer survival in patients with colorectal cancer carrying an increased number of the C risk allele at rs11614913 (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). In addition, this functional SNP has been associated with susceptibility to a wide variety of cancers, including lung [@B22], breast [@B23], gastric [@B24], head and neck [@B25], liver [@B26], and colorectal cancer [@B27], suggesting its important general role in carcinogenesis. The miRNA *hsa-miR-196a* is encoded at three locations in the mammalian homeobox (HOX) A, B, and C clusters, and the *hsa-miR-196a*-binding sites show evolutionarily conserved complementarity to mRNAs of several *HOX* genes [@B28].*hsa-miR-196a*-directed cleavage of *HOXB8* mRNA was observed in mouse embryos [@B28], and additional experiments revealed the down-regulated expression of *HOXA7*, *HOXB8*, *HOXC8*, and *HOXD8* in colorectal cancer cells [@B29]. *HOX* genes are known critical regulators of carcinogenesis [@B30], and our *in silico* analysis supports that altered *HOXA7*, *HOXB8*, and *AKT1* expression levels are correlated with colorectal cancer patient prognosis (Figure [2](#F2){ref-type="fig"}). Up-regulation of *hsa-miR-196a* expression has also been reported to be associated with a more aggressive disease course and unfavorable treatment outcomes in colorectal cancer [@B31]. However, the role of *U85* in cancer is currently unknown, thus warranting further study.

The significant association of the SNPs *hsa-mir-196a-2* rs11614913 and *U85* rs714775 with survival outcomes persisted after controlling for known prognostic factors and multiple testing, which should reduce the possibility of false-positive findings in this study. In addition, functional annotation supported the detected relationships between these sncRNA SNPs and the progression of colorectal cancer. However, these results should be interpreted with caution owing to several limitations of the present study, such as the relatively small sample size and retrospective nature, as well as the limitation of the sample including only cases from the Taiwanese population. Therefore, further studies are required to validate our results.

Nevertheless, the results of this study demonstrate that genetic variants of sncRNAs influence the survival of patients with colorectal cancer. Further studies are required to confirm the effects of these SNPs in larger and diverse populations and to understand the biological functions of sncRNAs in the progression of colorectal cancer.
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![**SNPs of sncRNA correlate with overall survival in colorectal cancer patients.** Kaplan-Meier analysis of overall survival according to genotypes at (A) *ACA23* rs2290423, (B) *hsa-mir-196a-2* rs11614913, and (C) *U85* rs714775. Numbers in parentheses indicate the number of patients.](ijmsv15p0217g001){#F1}

![**Prognostic value of the *hsa-miR-196a* target genes *HOXA7*, *HOXB8*, and *AKT1* in colorectal cancer.** Kaplan-Meier analysis of disease-free survival based on the risk score generated from (A) *HOXA7*, (B) *HOXB8*, and (C) *AKT1* expression levels obtained from the SurvExpress Colon-Metabase dataset. Numbers in parentheses indicate the number of patients.](ijmsv15p0217g002){#F2}

![**Pathway enrichment analysis of *hsa-mir-196a-2* target genes.** The top 20 significantly enriched (A) KEGG and (B) GO pathways of target genes for two mature miRNAs, *hsa-miR-196a-5p* and *hsa-miR-196a-3p*, originating from *hsa-mir-196a-2*. The left y-axis represents the significance according to the *P* value (log-scaled) and the right y-axis presents the number of genes in a particular pathway; the x-axis indicates the KEGG/GO pathways.](ijmsv15p0217g003){#F3}

###### 

Association of sncRNA SNPs with overall survival in colorectal cancer patients

  Type        Name             SNP          Chromosome   Position    *P*     *q*
  ----------- ---------------- ------------ ------------ ----------- ------- -----------
  C/D box     U94              rs3770069    2            86216585    0.824   0.818
  C/D box     HBII-429         rs9389034    6            133179703   0.714   0.818
  C/D box     U13              rs2732289    8            33490604    0.973   0.852
  C/D box     U14B             rs1541533    11           17052787    0.639   0.818
  C/D box     U25              rs1059292    11           62379627    0.650   0.818
  C/D box     14q(II-18)       rs12893444   14           100511971   0.451   0.818
  C/D box     U49B             rs11871958   17           16283558    0.403   0.818
  C/D box     HBII-135         rs4622550    17           16285326    0.369   0.818
  C/D box     U105             rs2305789    19           10079332    0.418   0.818
  C/D box     HBI-43           rs753213     20           17891492    0.109   0.493
  H/ACA box   U98b             rs792442     1            210592911   0.210   0.712
  H/ACA box   U19-2            rs17075508   5            172380368   0.708   0.818
  H/ACA box   ACA20            rs2295901    6            160121285   0.087   0.472
  H/ACA box   ACA29            rs3818299    6            160126621   0.201   0.712
  H/ACA box   ACA29            rs3818298    6            160126706   0.448   0.818
  H/ACA box   ACA17            rs2275159    9            138741147   0.399   0.818
  H/ACA box   ACA23            rs2290423    11           9406953     0.015   **0.145**
  H/ACA box   ACA32            rs1944108    11           93103823    0.874   0.818
  H/ACA box   U71d             rs788347     20           36495997    0.646   0.818
  miRNA       hsa-mir-943      rs1077020    4            1957991     0.648   0.818
  miRNA       hsa-mir-604      rs2368392    10           29874009    0.591   0.818
  miRNA       hsa-mir-608      rs4919510    10           102724768   0.862   0.818
  miRNA       hsa-mir-196a-2   rs11614913   12           52671866    0.004   **0.109**
  miRNA       hsa-mir-492      rs2289030    12           93752417    0.048   0.326
  miRNA       hsa-mir-423      rs6505162    17           25468309    0.783   0.818
  miRNA       hsa-mir-923      rs4796042    17           30502298    0.945   0.852
  scaRNA      U87              rs3792109    2            233849156   0.666   0.818
  scaRNA      U92              rs13302453   9            19053765    0.729   0.818
  scaRNA      U85              rs714775     12           6489663     0.016   **0.145**
  scaRNA      U93              rs3825546    14           95069573    0.802   0.818
  scaRNA      ACA47            rs2678770    17           72597029    0.802   0.818

Abbreviations: SNP, single nucleotide polymorphism; sncRNA, small non-coding RNA; miRNA, microRNA; scaRNA, small Cajal body-specific RNA.

*q* \< 0.20 are in boldface.

###### 

Univariate and multivariate analyses of sncRNA SNPs with overall survival

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP\         *N* (%)      *N* of deaths   5-year survival rate, %   *P*         Univariate analysis   Multivariate analysis\*                      
  Genotype                                                                                                                                           
  ------------ ------------ --------------- ------------------------- ----------- --------------------- ------------------------- ------------------ -----------
  rs2290423                                                                                                                                          

  TT           104 (57.8)   40              62.7                      **0.015**   1.00                                            1.00               

  TG           65 (36.1)    14              79.9                                  0.51 (0.28-0.95)      **0.032**                 0.67 (0.32-1.40)   0.282

  GG           11 (6.1)     2               90.9                                  0.35 (0.09-1.47)      0.152                     0.47 (0.11-2.07)   0.319

  Trend                                                                           0.54 (0.33-0.90)      **0.017**                 0.68 (0.39-1.18)   0.166

  rs11614913                                                                                                                                         

  TT           56 (32.7)    12              78.6                      **0.004**   1.00                                            1.00               

  TC           75 (43.9)    23              74.5                                  1.47 (0.73-2.96)      0.280                     1.58 (0.63-3.97)   0.327

  CC           40 (23.4)    20              49.1                                  2.79 (1.36-5.70)      **0.005**                 3.26 (1.27-8.38)   **0.014**

  Trend                                                                           1.69 (0.18-2.44)      **0.004**                 1.84 (1.15-2.96)   **0.012**

  rs714775                                                                                                                                           

  TT           85 (45.5)    34              61.5                      **0.016**   1.00                                            1.00               

  TC           85 (45.5)    24              74.1                                  0.66 (0.39-1.11)      0.115                     0.61 (0.33-1.14)   0.122

  CC           17 (9.1)     2               87.8                                  0.25 (0.06-1.04)      0.056                     0.12 (0.02-0.91)   **0.040**

  Trend                                                                           0.59 (0.39-0.91)      **0.017**                 0.50 (0.30-0.84)   **0.009**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: SNP, single nucleotide polymorphism; sncRNA, small non-coding RNA; CEA, carcinoembryonic antigen; HR, hazard ratio; CI, confidence interval.

\*Adjusted by age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement.

*P* \< 0.05 are in boldface.
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